266 related articles for article (PubMed ID: 17456617)
1. Use of proliferation signal inhibitors in the management of post-transplant malignancies--clinical guidance.
Campistol JM; Albanell J; Arns W; Boletis I; Dantal J; de Fijter JW; Mortensen SA; Neumayer HH; Øyen O; Pascual J; Pohanka E; Schena FP; Serón D; Sparacino V; Chapman JR
Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i36-41. PubMed ID: 17456617
[TBL] [Abstract][Full Text] [Related]
2. Kaposi's sarcoma in renal transplant recipients--the impact of proliferation signal inhibitors.
Campistol JM; Schena FP
Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i17-22. PubMed ID: 17456614
[TBL] [Abstract][Full Text] [Related]
3. Use of proliferation signal inhibitors in non-melanoma skin cancer following renal transplantation.
de Fijter JW
Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i23-6. PubMed ID: 17456615
[TBL] [Abstract][Full Text] [Related]
4. Post-transplant lymphoproliferative disorder--the potential of proliferation signal inhibitors.
Pascual J
Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i27-35. PubMed ID: 17456616
[TBL] [Abstract][Full Text] [Related]
5. Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology.
Valantine H
J Heart Lung Transplant; 2007 Jun; 26(6):557-64. PubMed ID: 17543777
[TBL] [Abstract][Full Text] [Related]
6. mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field?
Rostaing L; Kamar N
J Nephrol; 2010; 23(2):133-42. PubMed ID: 20155724
[TBL] [Abstract][Full Text] [Related]
7. Everolimus in clinical practice--renal transplantation.
Pascual J
Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii18-23. PubMed ID: 16815852
[TBL] [Abstract][Full Text] [Related]
8. Potential role of proliferation signal inhibitors on atherosclerosis in renal transplant patients.
Andrés V; Castro C; Campistol JM
Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii14-7. PubMed ID: 16815851
[TBL] [Abstract][Full Text] [Related]
9. The role of proliferation signal inhibitors in post-transplant malignancies.
Gutiérrez-Dalmau A; Campistol JM
Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i11-6. PubMed ID: 17360768
[TBL] [Abstract][Full Text] [Related]
10. Clinical insights for cancer outcomes in renal transplant patients.
Alberú J
Transplant Proc; 2010 Nov; 42(9 Suppl):S36-40. PubMed ID: 21095450
[TBL] [Abstract][Full Text] [Related]
11. Clinical recommendations for the use of everolimus in heart transplantation.
Manito N; Delgado JF; Crespo-Leiro MG; González-Vílchez F; Almenar L; Arizón JM; Díaz B; Fernández-Yáñez J; Mirabet S; Palomo J; Rodríguez Lambert JL; Roig E; Segovia J
Transplant Rev (Orlando); 2010 Jul; 24(3):129-42. PubMed ID: 20619801
[TBL] [Abstract][Full Text] [Related]
12. Conversion to a proliferation signal inhibitor in a patient with coronary artery disease--a case report.
Sparacino V; Calabrese S
Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii34-7. PubMed ID: 16815856
[TBL] [Abstract][Full Text] [Related]
13. Can mTOR inhibitors reduce the risk of late kidney allograft failure?
Ponticelli C
Transpl Int; 2008 Jan; 21(1):2-10. PubMed ID: 17635837
[TBL] [Abstract][Full Text] [Related]
14. Multidisciplinary insights on clinical guidance for the use of proliferation signal inhibitors in heart transplantation.
Zuckermann A; Manito N; Epailly E; Fiane A; Bara C; Delgado JF; Lehmkuhl H; Ross H; Eisen H; Chapman J; Valantine H
J Heart Lung Transplant; 2008 Feb; 27(2):141-9. PubMed ID: 18267219
[TBL] [Abstract][Full Text] [Related]
15. [Proliferation signal inhibitors: what therapeutic protocols are followed in 2009?].
Ladrière M
Nephrol Ther; 2009 Dec; 5 Suppl 6():S385-9. PubMed ID: 20129450
[TBL] [Abstract][Full Text] [Related]
16. [Replacing calcineurin inhibitors with proliferation signal inhibitors after kidney transplantation: indications, results, and disadvantages].
Audard V
Nephrol Ther; 2009 Dec; 5 Suppl 6():S395-9. PubMed ID: 20129452
[TBL] [Abstract][Full Text] [Related]
17. Conversion from calcineurin inhibitors to everolimus in kidney transplant recipients with malignant neoplasia.
Fernández A; Marcén R; Pascual J; Galeano C; Ocaña J; Arellano EM; Alfaro C; Villafruela JJ; Burgos FJ; Ortuño J
Transplant Proc; 2006 Oct; 38(8):2453-5. PubMed ID: 17097965
[TBL] [Abstract][Full Text] [Related]
18. Recurrent non-melanoma skin cancer: remission of field cancerization after conversion from calcineurin inhibitor- to proliferation signal inhibitor-based immunosuppression in a cardiac transplant recipient.
Signorell J; Hunziker T; Martinelli M; Koestner SC; Mohacsi PJ
Transplant Proc; 2010 Nov; 42(9):3871-5. PubMed ID: 21094874
[TBL] [Abstract][Full Text] [Related]
19. Late conversion to mammalian target of rapamycin inhibitor/proliferation signal inhibitors in kidney transplant patients: clinical experience in the last 5 years.
Sola E; Lopez V; Gutierrez C; Cabello M; Burgos D; Molina MG; Hernandez D
Transplant Proc; 2010 Oct; 42(8):2859-60. PubMed ID: 20970551
[TBL] [Abstract][Full Text] [Related]
20. Proliferation signal inhibitors in transplantation: questions at the cutting edge of everolimus therapy.
Chapman JR; Valantine H; Albanell J; Arns WA; Campistol JM; Eisen H; Frigerio M; Lehmkuhl H; Marcen R; Morris R; Nashan B; Pascual J; Pohanka E; Segovia J; Zuckermann A
Transplant Proc; 2007 Dec; 39(10):2937-50. PubMed ID: 18089298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
